Literature DB >> 3568194

Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes.

A Eastman.   

Abstract

Glutathione can modulate the toxicity of a variety of drugs, although its role in modulating toxicity by anticancer platinum drugs is ambivalent. At physiologically relevant concentrations, glutathione can inhibit the reaction between DNA and cis-dichloro(ethylenediamine)platinum(II) (cis-DEP). Glutathione can also react with monofunctional adducts in DNA to produce a glutathione-Pt-deoxyguanosine cross-link which would reduce the potential toxicity of the drug. The relative importance of these two mechanisms of detoxification is unknown, although both mechanisms probably contribute to glutathione modulation of platinum toxicity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3568194     DOI: 10.1016/0009-2797(87)90004-4

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  24 in total

1.  The trans influence in the modulation of platinum anticancer agent biology: the effect of nitrite leaving group on aquation, reactions with S-nucleophiles and DNA binding of dinuclear and trinuclear compounds.

Authors:  Eva I Montero; Junyong Zhang; Joseph J Moniodis; Susan J Berners-Price; Nicholas P Farrell
Journal:  Chemistry       Date:  2010-08-09       Impact factor: 5.236

Review 2.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II).

Authors:  L Pendyala; A V Arakali; P Sansone; J W Cowens; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Christian Dittrich; Jantien Wanders; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-05-29       Impact factor: 4.335

Review 5.  Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin.

Authors:  P Calsou; B Salles
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy.

Authors:  Ann M Moyer; Zhifu Sun; Anthony J Batzler; Liang Li; Daniel J Schaid; Ping Yang; Richard M Weinshilboum
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

7.  Differential properties of cisplatin and tetraplatin with respect to cytotoxicity and perturbation of cellular glutathione levels.

Authors:  M R Müller; K A Wright; P R Twentyman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Cross-linking protein glutathionylation mediated by O2-arylated bis-diazeniumdiolate "Double JS-K".

Authors:  Ryan J Holland; Anna E Maciag; Varun Kumar; Lei Shi; Joseph E Saavedra; Robert K Prud'homme; Harinath Chakrapani; Larry K Keefer
Journal:  Chem Res Toxicol       Date:  2012-11-09       Impact factor: 3.739

9.  Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells.

Authors:  G Chen; K J Hutter; W J Zeller
Journal:  Cell Biol Toxicol       Date:  1995-10       Impact factor: 6.691

Review 10.  Anticancer activity of metal complexes: involvement of redox processes.

Authors:  Ute Jungwirth; Christian R Kowol; Bernhard K Keppler; Christian G Hartinger; Walter Berger; Petra Heffeter
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.